Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCOT: Triamcinolone Acetonide for Open Globe Trauma
NCT02873026Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Oct 2014
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone acetonide in Ocular trauma and Proliferative Vitreoretinopathy (PVR), sponsored by Moorfields Eye Hospital. Primary endpoint: Improvement of visual acuity at 6 months. Started Oct 2014; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
Ocular traumaProliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT02873026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873026.